These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 8052700)
1. Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma. Lehnert S; Vestergaard J; Batist G; Aloui-Jamali MA Radiat Res; 1994 Aug; 139(2):232-9. PubMed ID: 8052700 [TBL] [Abstract][Full Text] [Related]
2. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity. Alaoui-Jamali MA; Panasci L; Centurioni GM; Schecter R; Lehnert S; Batist G Cancer Chemother Pharmacol; 1992; 30(5):341-7. PubMed ID: 1505071 [TBL] [Abstract][Full Text] [Related]
3. Radiation response of drug-resistant variants of a human breast cancer cell line. Lehnert S; Greene D; Batist G Radiat Res; 1989 Jun; 118(3):568-80. PubMed ID: 2727277 [TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Schecter RL; Woo A; Duong M; Batist G Cancer Res; 1991 Mar; 51(5):1434-42. PubMed ID: 1997182 [TBL] [Abstract][Full Text] [Related]
5. Radiation response of drug-resistant variants of a human breast cancer cell line: the effect of glutathione depletion. Lehnert S; Greene D; Batist G Radiat Res; 1990 Nov; 124(2):208-15. PubMed ID: 2247601 [TBL] [Abstract][Full Text] [Related]
6. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro. Barranco SC; Townsend CM; Weintraub B; Beasley EG; MacLean KK; Shaeffer J; Liu NH; Schellenberg K Cancer Res; 1990 Jun; 50(12):3614-8. PubMed ID: 2340510 [TBL] [Abstract][Full Text] [Related]
7. Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity. Schecter RL; Alaoui-Jamali MA; Woo A; Fahl WE; Batist G Cancer Res; 1993 Oct; 53(20):4900-6. PubMed ID: 8402679 [TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Bellamy WT; Dalton WS; Gleason MC; Grogan TM; Trent JM Cancer Res; 1991 Feb; 51(3):995-1002. PubMed ID: 1988143 [TBL] [Abstract][Full Text] [Related]
9. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194 [TBL] [Abstract][Full Text] [Related]
10. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765 [TBL] [Abstract][Full Text] [Related]
11. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype. Chen G; Teicher BA; Frei E Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973 [TBL] [Abstract][Full Text] [Related]
12. Chinese hamster pleiotropic multidrug-resistant cells are not radioresistant. Mitchell JB; Gamson J; Russo A; Friedman N; DeGraff W; Carmichael J; Glatstein E NCI Monogr; 1988; (6):187-91. PubMed ID: 3352763 [TBL] [Abstract][Full Text] [Related]
13. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434 [TBL] [Abstract][Full Text] [Related]
14. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. Xu BH; Gupta V; Singh SV Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro. Papadopoulou MV; Ji M; Khan SH; Bloomer WD Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738 [TBL] [Abstract][Full Text] [Related]
16. Intercellular transfer of drug resistance. Frankfurt OS; Seckinger D; Sugarbaker EV Cancer Res; 1991 Feb; 51(4):1190-5. PubMed ID: 1997161 [TBL] [Abstract][Full Text] [Related]
17. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo. Caffrey PB; Zhang Y; Frenkel GD Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cross-resistance between radiation and antineoplastic drugs. Ozols RF; Masuda H; Hamilton TC NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759 [TBL] [Abstract][Full Text] [Related]
19. Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells. Ripple M; Mulcahy RT; Wilding G J Urol; 1993 Jul; 150(1):209-14. PubMed ID: 8510259 [TBL] [Abstract][Full Text] [Related]